On May 29, Mylan Inc. (Nasdaq:MYL) announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline’s Malarone™ Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prophylaxis of Plasmodium falciparummalaria and the treatment of acute, uncomplicated P. falciparum malaria. Mylan Inc (NASDAQ:MYL) net profit margin is 9.00% and weekly performance is 5.13%. On last trading day company shares ended up $49.84. Analysts mean target price for the company is $60.47. Mylan Inc (NASDAQ:MYL) distance from 50-day simple moving average (SMA50) is 2.09%.
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shares fell -2.04% in last trading session and ended the day on $5.28. Gross Margin is 94.60 % and its return on assets is -99.70%. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) quarterly performance is 26.92%.
On May 28, Zoetis Inc (NYSE:ZTS) has received an average rating of “Buy” from the ten brokerages that are currently covering the stock, AnalystRatingsNetwork reports. Two research analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $30.00. Zoetis Inc (NYSE:ZTS) shares moved down -0.07% in last trading session and was closed at $30.70, while trading in range of $30.67 – $30.93. Zoetis Inc (NYSE:ZTS) year to date (YTD) performance is -5.65%.
Zacks cut shares of Salix Pharmaceuticals Ltd (NASDAQ:SLXP) from an outperform rating to a neutral rating in a research note issued to investors on Thursday. The firm currently has $122.00 price target on the stock. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) ended the last trading day at $114.08. Company weekly volatility is calculated as 2.46% and price to cash ratio as 18.78. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) showed a positive weekly performance of 0.89%.